AstraZeneca PLC
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Pascal Soriot
- Full Time Employees
- 96,100
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1 Francis Crick Avenue Cambridge CA United Kingdom CB2 0AA
- IPO Date
- Sep 21, 2007
- Website
- astrazeneca.com
- Similar Companies
- Business
- AstraZeneca PLC (AZN.L), a British-Swedish multinational biopharmaceutical company headquartered in Cambridge, United Kingdom, and founded in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group PLC, discovers, develops, manufactures and commercializes prescription medicines across three core therapy areas: Oncology; BioPharmaceuticals, including Cardiovascular, Renal & Metabolism (CVRM) products such as Farxiga (dapagliflozin) for heart failure, chronic kidney disease and type 2 diabetes, Lokelma (sodium zirconium cyclosilicate) for hyperkalaemia, and Brilinta (ticagrelor) for cardiovascular disease, as well as Respiratory & Immunology offerings including Symbicort (budesonide/formoterol), Breztri (budesonide/glycopyrronium/formoterol), Fasenra (benralizumab) for severe eosinophilic asthma and EGPA, Saphnelo (anifrolumab) for systemic lupus erythematosus, and Pulmicort (budesonide); Rare Disease and BioPharmaceuticals treatments; and Vaccines & Immune Therapies; with key Oncology brands encompassing Tagrisso (osimertinib) for EGFR-mutant non-small cell lung cancer, Imfinzi (durvalumab) for bladder cancer, lung cancer and gastric cancers, Lynparza (olaparib) as a PARP inhibitor across ovarian, breast, prostate and pancreatic cancers, Enhertu (trastuzumab deruxtecan) for HER2-positive breast, gastric and other cancers, and Calquence (acalabrutinib) for haematological malignancies. The company conducts R&D at major sites in Cambridge (UK), Gaithersburg (Maryland, US), Gothenburg (Sweden) and Warsaw (Poland), operates sales in over 130 countries with more than 80,000 employees worldwide, and maintains manufacturing facilities across the US, Europe and other regions. Recent developments include the acquisition of Belgian biotech EsoBiotec for up to $1 billion in March 2025 to advance in vivo cell therapy platform ENaBL for cancer treatments; exercise of an option to acquire obesity-focused startup SixPeaks Bio AG in October 2025; completion of the acquisition of Amolyt Pharma for $1.05 billion to bolster rare endocrine disease pipeline; a licensing deal with Algen Biotechnologies in October 2025 worth up to $555 million for AI-identified gene therapies targeting immune disorders; a collaboration with Alteogen for subcutaneous oncology formulations using Hybrozyme technology; significant US manufacturing expansions such as a $445 million facility upgrade in Coppell, Texas, to double Lokelma production, a new $4.5 billion API plant in Virginia, and a $2 billion investment in Maryland for biologics and clinical production; alongside positive clinical trial readouts for Enhertu in breast cancer, Imfinzi in bladder and gastric cancers, baxdrostat in hypertension, Breztri in asthma, and Fasenra in hypereosinophilic syndrome, with plans for at least 15 new drug launches by 2030.
Company News
AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
27,056 AstraZeneca Plc $AZN Shares Acquired by International Assets Investment Management LLC
1,929,102 Shares of AstraZeneca Plc $AZN Acquired by Bank Julius Baer & Co. Ltd Zurich
AstraZeneca: 3 Key Takeaways for Long-Term Investors
AstraZeneca (NYSE:AZN) Share Price Crosses Above 200 Day Moving Average – Time to Sell?
AstraZeneca Plc $AZN Shares Acquired by Brian Low Financial Group LLC
AstraZeneca (LON:AZN) Share Price Crosses Above Two Hundred Day Moving Average – Time to Sell?
AstraZeneca PLC (AZN) Q3 2026 Earnings Call Transcript
AstraZeneca Q3 Earnings Call Highlights
AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth
AstraZeneca Stock Rallies on Q3 Earnings Beat, Double-Digit Oncology Growth
Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
AstraZeneca CFO on AI, Earnings, Restructuring Plan
AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock
AstraZeneca results: 9M and Q3 2026
FTSE 100 set for monthly gains; AstraZeneca up after results
AstraZeneca Posts Revenue, Profit Growth on Strong Cancer-Drug Sales
AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing
Allspring Emerging Growth Fund: Q3 2026 Top Contributors And Detractors
Breast Cancer Canada and AstraZeneca Canada Advance Next-Generation Survivorship Research